pharmaceuticals
pharmaceuticals Articles
Johnson & Johnson has announced that it will accelerate initiation of its early stage first-in-human clinical trial for the treatment of COVID-19. Shares got a mild boost on Wednesday from the news.
Published:
Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.
Published:
Investors look at Aytu BioScience as it looks at expanding in the COVID testing field.
Published:
Some mergers can add a nice shot in the arm for an acquirer. After years of being focused on Humira, AbbVie has now completed its acquisition of Allergan.
Published:
Brokerage firm Canaccord Genuity issued some key takeaways on a few different companies at ASCO. 24/7 Wall St. has also included some recent data on the stock.
Published:
PhaseBio Pharmaceuticals shares jumped early on Thursday after the company announced that it received an authorization from the FDA regarding its COVID-19 treatment.
Published:
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
Published:
Diffusion Pharmaceuticals shares pushed higher to start the week after it announced a critical update from the FDA concerning its potential treatment for COVID-19 patients displaying severe...
Published:
Merck shares jumped on Tuesday after the company announced that it has made deals to develop drugs in the fight against COVID-19.
Published:
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
Published:
Navidea Biopharmaceuticals shares more than doubled to close out the week after the company provided an update from its midstage study in patients with active rheumatoid arthritis.
Published:
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
Published:
Wedbush took a closer look at some of the companies in its coverage universe that are set to present at ASCO and what the impact may be going forward.
Published:
These are five of the best stocks in a sector that has been humming along in what has been a turbulent year. They are all included on the Goldman Sachs Conviction List too.
Published:
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
Published: